As of the latest Form 4 filed May 20, 2026.
What Opus Genetics, Inc. insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 31 most recent filings for IRD.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | 2026-05-18 | Foundation Fighting Blindness Retinal Degeneration Fund Director | SSale | −1.70M | $4.35 | $7.39M | No | Form 4 ↗ |
| 2026-04-27 | 2026-04-23 | YERXA BENJAMIN R President | SSale | −7.47K | $5.24 | $39.1K | No | Form 4 ↗ |
| 2026-04-27 | 2026-04-23 | SCHACHLE JOSEPH K Chief Operating Officer | SSale | −4.70K | $5.22 | $24.5K | No | Form 4 ↗ |
| 2026-04-27 | 2026-04-23 | Zaremba Rabourn Amy Head of Fin. Quality Assurance | SSale | −1.64K | $5.20 | $8.54K | No | Form 4 ↗ |
| 2026-04-27 | 2026-04-23 | Magrath George Chief Executive Officer | SSale | −9.51K | $5.22 | $49.6K | No | Form 4 ↗ |
| 2026-04-27 | 2026-04-23 | Jayagopal Ashwath Chief Scientific & Dev. Ofc. | SSale | −7.54K | $5.19 | $39.2K | No | Form 4 ↗ |
| 2026-04-27 | 2026-04-23 | Gagnon Robert E. Chief Financial Officer | SSale | −7.84K | $5.18 | $40.7K | No | Form 4 ↗ |
| 2026-04-22 | 2026-04-20 | Rodgers Richard J Director | AAward | +24.4K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-22 | 2026-04-20 | MANUSO JAMES S J Director | AAward | +24.4K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-22 | 2026-04-20 | Graves Adrienne L Director | AAward | +24.4K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-22 | 2026-04-20 | Gallagher Cam Director | AAward | +24.4K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-22 | 2026-04-20 | Benton Susan Director | AAward | +24.4K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-22 | 2026-04-20 | Bennett Jean Director | AAward | +24.4K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-22 | 2026-04-20 | Ainsworth Sean Director | AAward | +24.4K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-18 | 2026-03-16 | SCHACHLE JOSEPH K Chief Operating Officer | SSale | −3.72K | $5.25 | $19.5K | No | Form 4 ↗ |
| 2026-03-18 | 2026-03-16 | Zaremba Rabourn Amy Head of Fin. Quality Assurance | SSale | −2.82K | $5.25 | $14.8K | No | Form 4 ↗ |
| 2026-03-18 | 2026-03-16 | Magrath George Chief Executive Officer | SSale | −24.4K | $5.21 | $127K | No | Form 4 ↗ |
| 2026-03-18 | 2026-03-16 | Jayagopal Ashwath Chief Scientific & Dev. Ofc. | SSale | −3.72K | $5.12 | $19.0K | No | Form 4 ↗ |
| 2026-01-26 | 2026-01-22 | YERXA BENJAMIN R President | AAward | +400K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-26 | 2026-01-22 | SCHACHLE JOSEPH K Chief Operating Officer | AAward | +250K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-26 | 2026-01-22 | Zaremba Rabourn Amy Head of Fin. Quality Assurance | AAward | +86.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-26 | 2026-01-22 | Magrath George Chief Executive Officer | AAward | +484K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-26 | 2026-01-22 | Jayagopal Ashwath Chief Scientific & Dev. Ofc. | AAward | +400K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-26 | 2026-01-22 | Gagnon Robert E. Chief Financial Officer | AAward | +400K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-21 | 2026-01-18 | Zaremba Rabourn Amy Head of Fin. Quality Assurance | FTax | −3.39K | $2.10 | $7.12K | No | Form 4 ↗ |
| 2026-01-13 | 2026-01-10 | Zaremba Rabourn Amy Head of Fin. Quality Assurance | FTax | −3.95K | $1.93 | $7.62K | No | Form 4 ↗ |
| 2026-01-08 | 2026-01-06 | Gallagher Cam Director | AAward | +67.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-12-31 | 2025-12-31 | Gallagher Cam Director | AAward | +33.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-12-31 | 2025-12-29 | Gallagher Cam, Director | PPurchase | +83.0K | $1.97 | $163K | No | Form 4 ↗ |
| 2025-12-31 | 2025-12-29 | Gallagher Cam, Director | PPurchase | +81.0K | $1.98 | $160K | No | Form 4 ↗ |
| 2025-12-11 | 2025-12-09 | Foundation Fighting Blindness Retinal Degeneration Fund Director | SSale | −4.00M | $2.15 | $8.60M | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also IRD’s full analysis or the market-wide insider trading feed. The tabs above jump to IRD’s other SEC data.
Source: SEC Form 4 filings for IRD, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.